source
- Biogen looks to Apellis acquisition to boost lagging Leqembi salesBiogen CEO Chris Viehbacher said the company's Alzheimer's drug Leqembi has underperformed since its 2023 launch. The drug, co-developed with Eisai, has struggled to meet sales expectations, promp…
- Medicare proposal threatens funding for remote patient monitoring programsMedicare announced a proposal to sharply reduce reimbursement for remote patient monitoring services, reversing earlier policy support. The change would cut payments to firms that supply technolog…